



Bill Gates visited Intercell to discuss vaccine approaches for developing countries

- » Bill Gates visited Intercell to gain insight into the Company's programs
- » Intercell's Management team and Bill Gates discussed the need for vaccines to fight infectious diseases and to contribute to people's health worldwide

Vienna (Austria), July 20, 2010 – Intercell AG (VSE: ICLL) is pleased to announce that Bill Gates, Co-chair of the Bill & Melinda Gates Foundation today has visited Intercell's headquarter in Vienna for a close look at the Company's product pipeline and innovative vaccine technologies to fight infectious diseases. By developing innovative vaccines, Intercell makes an active contribution to people's health.

Bill and Melinda Gates recently committed USD 10 billion over the next 10 years to help research, develop and deliver vaccines for the world's poorest countries. The foundation is convinced that vaccines are one of the most effective health interventions ever developed. The goal of the Bill & Melinda Gates Foundation is to increase the use of effective but underused vaccines and introduce new vaccines to prevent a total of 4 million deaths per year.

Getting cost-effective vaccines to the people in developing countries who need them is complicated and a significant challenge for the vaccine industry. Intercell is aware of this challenge and develops vaccines with substantial medical needs. The company already works with international organizations dedicated to combating illness in developing countries, like PATH (Pneumococcus vaccines candidate) and AERAS Global Tuberculosis Foundation (Tuberculosis vaccine). Moreover, the Company's first product against Japanese Encephalitis and its Travelers' Diarrhea vaccine candidate can bring innovation to all geographic areas. Intercell's vaccine patch technology with its ease of administration and the potential room-temperature stability, is expected to also increase accessibility to vaccines among the world's poorest populations.

During his stay in Vienna, Bill Gates and Intercell's Management team discussed also potential ways of future cooperation to develop novel and innovative vaccines for the developing world.

"It was a big honor of having Bill Gates visit and stay with us. Partnerships focused on reducing infectious diseases can save millions of lives and are also helping to build a stronger foundation for the development and distribution of vaccines. As a vaccine company, Intercell is committed to improve the health of all people and contributes to support significant and lasting change," stated Gerd Zettlmeissl, CEO of Intercell.

About Intercell AG

Intercell AG is an innovative biotechnology company that develops novel vaccines for the prevention and treatment of infectious diseases with substantial unmet medical needs. Intercell's vaccine to prevent Japanese Encephalitis is the Company's first product on the market.





The Company's technology platform includes an antigen-discovery system and human anti-infective monoclonal antibody discovery system, adjuvants and a novel patch-based delivery system (Vaccine Patch, Vaccine Enhancement Patch). Based on these technologies, Intercell has strategic partnerships with a number of global pharmaceutical companies, including GSK, Novartis, Merck & Co., Inc., sanofi-aventis, and Pfizer (formerly Wyeth).

The Company's pipeline of investigational products includes a Travelers' Diarrhea Vaccine Patch (Phase III), a Pseudomonas vaccine candidate (Phase II), a vaccine to prevent Pandemic Influenza combining our Vaccine Enhancement Patch with an injected vaccine (Phase II), a vaccine program for S. aureus, which is being developed with Merck & Co., Inc. (Phase II/III), as well as a vaccine candidate for Pneumococcus (Phase I). In addition, further products focused on infectious diseases are in pre-clinical development.

Intercell is listed on the Vienna stock exchange under the symbol "ICLL" (U.S. level one ADR symbol "INRLY").

For more information, please visit: www.intercell.com

Contact

Intercell AG

Corporate Communications

Campus Vienna Biocenter 3, A-1030 Vienna

P: +43-1-20620-1222

Mail to: Communications@intercell.com

This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.